In February 2022, the National Institute of Social and Care Excellence (NICE) began drafting guidance around treating obesity with semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist licensed for this use.51 It is administered subcutaneously once weekly. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.